CSL (ASX:CSL) said Tuesday CSL Seqirus was awarded a contract by the Health Emergency Preparedness and Response Authority to support the pandemic preparedness plans of 17 European Union and European Economic Area member states as well as the European Commission.
Under the contract, 27 million doses of pandemic influenza vaccine have been reserved with CSL Seqirus, which can be ordered by the participating countries in the event of an influenza pandemic, according to a statement.
The deal requires CSL Seqirus to be prepared to rapidly manufacture and deliver these vaccine doses. The doses will be produced at the company's manufacturing site in Liverpool, UK.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。